Gilead Sciencesvs.Regeneron
GILD vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 2.4× larger than Regeneron by market cap; year to date, Gilead Sciences leads (+19.8% vs −4.2%).
Side by side
| GILD | REGN | |
|---|---|---|
| Market cap | $186B | $76.1B |
| Price | $151.17 | $746.54 |
| Today | +2.8% | +0.9% |
| Return YTD | +19.8% | −4.2% |
| Return 1Y | +24.4% | +31.2% |
| Since June 26, 2026 | +18.2% | +18.0% |
| P/E | — | 17.6 |
| P/S | 6.1 | 4.9 |
| P/B | 15.7 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More GILD & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.